Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (31)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fennell, T. R.
Right arrow Articles by Sumner, S. C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fennell, T. R.
Right arrow Articles by Sumner, S. C. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Toxicological Sciences 71, 164-175 (2003)
Copyright © 2003 by the Society of Toxicology

BIOTRANSFORMATION AND TOXICOKINETIC

Comparison of the Hemoglobin Adducts Formed by Administration of N-Methylolacrylamide and Acrylamide to Rats

Timothy R. Fennell*,1, Rodney W. Snyder*,2, Wojciech L. Krol*,3 and Susan C. J. Sumner*,4

* CIIT Centers for Health Research, P.O. Box 12137, Research Triangle Park, North Carolina 27709

Acrylamide (AM) and N-methylolacrylamide (NMA) are used in the formulation of grouting materials. AM undergoes metabolism to a reactive epoxide, glycidamide (GA). Both AM and GA react with hemoglobin to form adducts that can be related to exposure to AM. The objective of this study was to evaluate the extent to which NMA could form the same adducts as AM. N-(2-carbamoylethyl)valine (AAVal derived from AM) and N-(2-carbamoyl-2-hydroxyethyl)valine (GAVal derived from GA) were measured following a single oral dose of AM (50 mg/kg) or NMA (71 mg/kg) in male F344 rats. AAVal and GAVal were measured by a modified Edman degradation to produce phenylthiohydantoin derivatives and liquid chromatography/tandem mass spectrometry. In AM-treated rats, AAVal was 21 ± 1.7-pmol/mg globin (mean ± SD, n = 4), and GAVal was 7.9 ± 0.8 pmol/mg. In NMA-treated rats, AAVal was 41 ± 4.9 pmol/mg, and GAVal was 1.4 ± 0.1 pmol/mg. Whether AAVal was derived from reaction of NMA with globin followed by loss of the hydroxymethyl group, or loss of the hydroxymethyl group to form AM prior to reaction with globin, is not known. However, the higher ratio of AAVal:GAVal in NMA-treated rats (29 vs. 2.6 in AM-treated rats) suggests that reaction of NMA with globin is the predominant route to AAVal in NMA-treated rats. The detection of GAVal in NMA-treated rats indicates oxidation of NMA, either directly or following conversion to AM. The lower levels of GAVal on NMA administration suggest that a much lower level of epoxide was formed than compared with AM treatment.

Key Words: acrylamide; glycidamide; N-methylolacrylamide; hemoglobin; adduct.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Toxicol SciHome page
E. Zeiger, L. Recio, T. R. Fennell, J. K. Haseman, R. W. Snyder, and M. Friedman
Investigation of the Low-Dose Response in the In Vivo Induction of Micronuclei and Adducts by Acrylamide
Toxicol. Sci., January 1, 2009; 107(1): 247 - 257.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
H. W. Vesper, J. T. Bernert, M. Ospina, T. Meyers, L. Ingham, A. Smith, and G. L. Myers
Assessment of the Relation between Biomarkers for Smoking and Biomarkers for Acrylamide Exposure in Humans
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2471 - 2478.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
T. Bjellaas, P. T. Olesen, H. Frandsen, M. Haugen, L. H. Stolen, J. E. Paulsen, J. Alexander, E. Lundanes, and G. Becher
Comparison of Estimated Dietary Intake of Acrylamide with Hemoglobin Adducts of Acrylamide and Glycidamide
Toxicol. Sci., July 1, 2007; 98(1): 110 - 117.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
B. I. Ghanayem, L. P. McDaniel, M. I. Churchwell, N. C. Twaddle, R. Snyder, T. R. Fennell, and D. R. Doerge
Role of CYP2E1 in the Epoxidation of Acrylamide to Glycidamide and Formation of DNA and Hemoglobin Adducts
Toxicol. Sci., December 1, 2005; 88(2): 311 - 318.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
T. R. Fennell, S. C.J. Sumner, R. W. Snyder, J. Burgess, R. Spicer, W. E. Bridson, and M. A. Friedman
Metabolism and Hemoglobin Adduct Formation of Acrylamide in Humans
Toxicol. Sci., May 1, 2005; 85(1): 447 - 459.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
B. A. Wetmore and B. A. Merrick
Invited Review: Toxicoproteomics: Proteomics Applied to Toxicology and Pathology
Toxicol Pathol, October 1, 2004; 32(6): 619 - 642.
[Abstract] [PDF]

Home page
 Toxicol SciHome page
S. C. J. Sumner, C. C. Williams, R. W. Snyder, W. L. Krol, B. Asgharian, and T. R. Fennell
Acrylamide: A Comparison of Metabolism and Hemoglobin Adducts in Rodents following Dermal, Intraperitoneal, Oral, or Inhalation Exposure
Toxicol. Sci., October 1, 2003; 75(2): 260 - 270.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
E. Dybing and T. Sanner
Risk Assessment of Acrylamide in Foods
Toxicol. Sci., September 1, 2003; 75(1): 7 - 15.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.